Featured Stories
SCHOTT Pharma Announces Innovative Cartridge Nesting for Efficiency and Sustainability
SCHOTT Pharma, the pharma drug containment solutions and delivery systems company, has unveiled a groundbreaking nest design for ready-to-use cartridges to improve operational efficiency and sustainability for pharmaceutical manufacturing. The new design optimizes the arrangement of cartridges, reducing the risk of breakage and contamination during high-speed automated filling, and enhancing productivity by streamlining the fill-and-finish process, resulting in faster handling and increased throughput.
Samabriva Expands Biomanufacturing Capabilities with New Belgian Facility
French biotech, Samabriva, has unveiled a significant expansion with a new 1,400-square-meter biomanufacturing facility located in Liege, Belgium, to aid the transition from research and development to industrial-scale production. The state-of-the-art facility is equipped with proprietary bioreactors specifically designed for hairy root culture, enabling the production of natural molecules for pharmaceutical applications.
Adragos Pharma Expands Global Footprint with Swiss Acquisition
German CDMO Adragos Pharma has acquired Swiss manufacturer Baccinex, marking the addition of its sixth global manufacturing site and strengthening its position in sterile manufacturing. The facility, based in Courroux, Switzerland, specializes in fill-finish services for clinical trials and small-to-medium-scale commercial production. It will continue to operate under the leadership of founder and CEO Ursula Bausch.
National Resilience Confirms Layoffs Amid Expansion and Leadership Change
Biomanufacturing CDMO, National Resilience, has announced plans to lay off approximately 105 employees at its Alachua, Florida facility as part of a strategic pivot away from government business toward commercial development and manufacturing. The restructuring coincides with a leadership change, as CEO Rahul Singhvi steps down and is replaced by William Marth. However, the company will continue to expand elsewhere, including a USD 225 mn investment in Cincinnati and creating 440 new jobs at its West Chester, Ohio facility.
Agenus Pivots to CDMO Services Amid Regulatory Setbacks
Massachusetts biotech Agenus is undergoing its second reorganization in 16 months, pivoting to include CDMO services at its 25,000-square-foot Berkeley clinical facility and 83,000-square-foot Emeryville commercial plant for third-party biologics manufacturing.
Novo Holdings Receives EU Approval for Catalent Acquisition
The European Commission has granted unconditional approval for Novo Holdings A/S to acquire Catalent, Inc., with the acquisition expected to close by the end of 2024. Catalent's CEO Alessandro Maselli has welcomed the approval, while Novo Holdings' Senior Partner Jonathan Levy affirmed their commitment to supporting Catalent's future growth. The transaction remains subject to final regulatory clearances and closing conditions.
Boryung Corp. and Lotus Pharmaceutical Forge CDMO Partnership for Anticancer Drug Production
South Korean pharma, Boryung Corp., has announced a partnership with Taiwanese CDMO Lotus Pharmaceutical, for services focused on cytotoxic drugs and will take on the role of manufacturing an anticancer injection for Lotus.
BIOSECURE Act Excluded from U.S. Defense Bill, Boosting Chinese Biotech Firms
The BIOSECURE Act - intended to address national security concerns by restricting U.S. government contracts with certain Chinese biotechnology companies - has been omitted from the 2025 National Defense Authorization Act (NDAA), providing a temporary reprieve to targeted Chinese firms like WuXi AppTec, WuXi Biologics, and BGI Group.
SK pharmteco Unifies Global CDMO Brands to Streamline Drug Development Services
Californian-based, SK pharmteco, has announced a brand unification initiative, bringing together several respected organizations under its umbrella to create a global CDMO. SK biotek, SK biotek Ireland, Center for Breakthrough Medicines, Yposkesi, AMPAC Fine Chemicals, and AMPAC Analytical, will now combine to operate as SK pharmteco, providing a comprehensive range of services from early-stage development to commercial manufacturing and analytical testing.
OneSource Expands GLP-1 Drug-Device Capacity as Demand Soars
India-based CDMO, OneSource Specialty Pharma, is expanding its capacity to manufacture GLP-1 drug-device combinations, driven by growing global demand for diabetes and obesity treatments. The company, which specializes in drug-device combinations, including cartridge filling, assembly, and fill-finish, recently raised funding through equity issuance to fund this expansion.
Lonza Drops CHI Business to Focus on CDMO Services
Swiss manufacturing company, Lonza, has announced a strategic shift to focus on its CDMO business. The company will restructure its existing CDMO business into three new units - integrated biologics, advanced synthesis, and specialized modalities - as it focuses on its ambition to achieve and maintain leadership across therapeutic modalities.
Outsource or Die? How CDMOs Will Shape Pharma in 2025 and Beyond
Overall, 2024 was a good year to be working in the CDMO industry, but will the outlook stay positive for 2025?
Forecasts predict a steady rise in continuing growth trends from 2024, with estimates indicating the global pharmaceutical CDMO market is set to grow from USD 184.90 bn in 2024 to USD 197.40 bn in 2025, and looking further ahead, predicted to reach USD 368.70 bn by 2034.
BioDuro Appoints Alan Findlater as New Chief Commercial Officer
CRDMO BioDuro has announced the appointment of Alan Findlater as their new CCO, who brings over 25 years of senior commercial leadership experience in the life sciences and pharmaceutical services industry to his new role. Findlater has experience leading high-performing teams and managing complex product and service portfolios, with his expertise also extending to executing successful strategic growth initiatives on a global scale and building high-value partnerships with industry leaders such as Amgen, Pfizer, and Roche.
KPMG Life Sciences CEO Outlook Report
The KPMG 2024 Life Sciences CEO Outlook report reveals that despite economic and geopolitical uncertainties, many CEOs remain optimistic. Growth prospects, new technologies, business models, and sustainability all feature within the report. 79% of CEOs expressed confidence in their companies' growth, with many planning to expand their workforce and engage in acquisitions.
Celltrion to Break Ground on CDMO Plant in 2025
Celltrion, a leading South Korean biosimilar developer, has announced plans to enter the CDMO market, investing 1.5 trillion won (USD 1 bn) to construct a 200,000-liter production facility in Korea.
To support this expansion, Celltrion will open R&D centers in India, the US, and Europe, hiring 500 Ph.D.-level researchers, aiming to offer a comprehensive range of CDMO services related to monoclonal antibodies, bispecific antibodies, and ADCs.
Dyadic Secures Gates Foundation Grant to Develop Affordable Antibodies for RSV and Malaria
Florida biotech, Dyadic International, has secured a USD 3 mn grant from the Gates Foundation to develop affordable monoclonal antibodies for RSV and malaria, using its C1 protein production platform to address the limited access to mAb treatments in low- and middle-income countries.
Bristol Myers Squibb Implements Layoffs in New Jersey Amid Cost-Cutting Measures
BMS has announced plans to lay off 195 employees across its two facilities in Lanceville, New Jersey as part of a broader cost-cutting initiative. In addition to the New Jersey layoffs, BMS had previously announced plans to reduce its global workforce by approximately 3,300 positions, representing about 5% of its total employees.
Roche Acquires Poseida Therapeutics, Boosting Cell Therapy Portfolio
Roche Holdings, Inc. has agreed to acquire Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in allogeneic cell therapies and genetic medicines, integrating the company into Roche's Pharmaceuticals Division, and enhancing their capabilities in allogeneic cell therapy.
The acquisition brings Poseida's innovative pipeline which includes a proprietary non-viral technology platform, which enables the development of allogeneic, T stem cell memory (T SCM)-rich CAR-T therapies, which include hematologic malignancies, solid tumors, and autoimmune diseases.
Schreiner MediPharm's Innovative Label Enhances WuXi XDC's Clinical Trials
Schreiner MediPharm, a leading developer of functional labels for healthcare, has created a specialized Light-Protect-Label for CRDMO, WuXi XDC, to support the dual needs of light protection and drug blinding, to accelerate the process for a novel ADC in clinical trials.
Hovione Expands Cork Facility, Boosts Spray Drying Capacity
Pharmaceutical CDMO, Hovione, has unveiled a multi-million expansion of its manufacturing facility in Cork, Ireland, which will double the company’s existing spray drying capacity, and reinforce its position as a global leader in spray drying technology for pharmaceutical applications, such as inhalable therapies and oral medications.